William K. Decker

Baylor College of Medicine — United States

Immunology and Microbiology · Life Sciences

29h-index6.2kcitations163works1.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immunotherapy and Immune Responses(61), Immune Cell Function and Interaction(37), CAR-T cell therapy research(21), Cancer Immunotherapy and Biomarkers(18), Hematopoietic Stem Cell Transplantation(17)

Publications161 total

Investigating the mechanistic basis for dendritic cell-intrinsic AIMp1 regulation of dendritic cell maturation and anti-tumor immunity 4111
The Journal of Immunology·2025
Development of small molecule modulators of CTLA-4 as a novel strategy for safe and effective immunotherapies 9305
The Journal of Immunology·2025Open Access
540 Phase I trial of DOC1021 cell-based immunotherapy for resectable or borderline resectable pancreatic ductal adenocarcinoma
Regular and Young Investigator Award Abstracts·2025Open Access
Bypassing cisplatin resistance in Nrf2 hyperactivated head and neck cancer through effective PI3Kinase targeting
British Journal of Cancer·2025Open Access
Supplementary figure 7 from Nrf2 Hyperactivation as a Driver of Radiotherapy Resistance and Suppressed Antitumor Immunity in Head and Neck Squamous Cell Carcinoma
2025Open Access
Supplementary Table 1 from Nrf2 Hyperactivation as a Driver of Radiotherapy Resistance and Suppressed Antitumor Immunity in Head and Neck Squamous Cell Carcinoma
2025Open Access
Supplementary figure 3 from Nrf2 Hyperactivation as a Driver of Radiotherapy Resistance and Suppressed Antitumor Immunity in Head and Neck Squamous Cell Carcinoma
2025Open Access
Supplementary Table 2 from Nrf2 Hyperactivation as a Driver of Radiotherapy Resistance and Suppressed Antitumor Immunity in Head and Neck Squamous Cell Carcinoma
2025Open Access
Supplementary figure 2 from Nrf2 Hyperactivation as a Driver of Radiotherapy Resistance and Suppressed Antitumor Immunity in Head and Neck Squamous Cell Carcinoma
2025Open Access
Supplementary figure 4 from Nrf2 Hyperactivation as a Driver of Radiotherapy Resistance and Suppressed Antitumor Immunity in Head and Neck Squamous Cell Carcinoma
2025Open Access
Data from Nrf2 Hyperactivation as a Driver of Radiotherapy Resistance and Suppressed Antitumor Immunity in Head and Neck Squamous Cell Carcinoma
2025Open Access
Supplementary Materials & Methods1 from Nrf2 Hyperactivation as a Driver of Radiotherapy Resistance and Suppressed Antitumor Immunity in Head and Neck Squamous Cell Carcinoma
2025Open Access
Supplementary figure 5 from Nrf2 Hyperactivation as a Driver of Radiotherapy Resistance and Suppressed Antitumor Immunity in Head and Neck Squamous Cell Carcinoma
2025Open Access
Supplementary figure 6 from Nrf2 Hyperactivation as a Driver of Radiotherapy Resistance and Suppressed Antitumor Immunity in Head and Neck Squamous Cell Carcinoma
2025Open Access
Supplementary figure 1 from Nrf2 Hyperactivation as a Driver of Radiotherapy Resistance and Suppressed Antitumor Immunity in Head and Neck Squamous Cell Carcinoma
2025Open Access
Abstract A114: CCK-B Receptor Blockade with Proglumide Enhances Antitumor Activity and Persistence of CD8+CD161+ CAR-T Cells in Pancreatic Ductal Adenocarcinoma
Cancer Research·2025
Nrf2 Hyperactivation as a Driver of Radiotherapy Resistance and Suppressed Antitumor Immunity in Head and Neck Squamous Cell Carcinoma
Clinical Cancer Research·2025· 1 citedOpen Access
A randomized, double-blind, placebo-controlled study of daily cannabidiol for the treatment of canine osteoarthritis pain: erratum
Pain·2025
Vaccination by homologous antigenic loading with DOC1021 as adjuvant therapy for glioblastoma: Phase I clinical trial results.
Journal of Clinical Oncology·2025
Phase I Analysis of DOC1021, A Cell-based Vaccination Platform for Adjuvant Therapy of Glioblastoma (S29.004)
Neurology·2025
page 1 of 9Next →

Frequent Co-authors

Elizabeth J. Shpall(15), Simon N. Robinson(13), Vanaja Konduri(11), Matthew M. Halpert(11), Catherine M. Bollard(9), Jonathan M. Levitt(9), David Steiner(9), Dongxia Xing(8), Jonathan Vazquez‐Perez(6), Sufang Li(6), Richard E. Champlin(6), Hong Yang(6), William J. Craigen(5), Dan Liang(5), Barbara Savoldo(4), Gianpietro Dotti(4), Margaret J. Sampson(4), Dajun Xing(4), Silke Paust(4), Nina Shah(4)